What is Leerink Partnrs’ Estimate for LVTX Q1 Earnings?

LAVA Therapeutics (NASDAQ:LVTX) – Investment analysts at Leerink Partnrs issued their Q1 2025 earnings per share (EPS) estimates for shares of LAVA Therapeutics in a research report issued to clients and investors on Thursday, December 12th. Leerink Partnrs analyst D. Graybosch expects that the company will earn ($0.23) per share for the quarter. Leerink Partnrs currently has a “Hold” rating on the stock. The consensus estimate for LAVA Therapeutics’ current full-year earnings is ($1.28) per share. Leerink Partnrs also issued estimates for LAVA Therapeutics’ Q2 2025 earnings at ($0.23) EPS, Q3 2025 earnings at ($0.22) EPS and Q4 2025 earnings at ($0.23) EPS.

A number of other brokerages have also recently commented on LVTX. JMP Securities restated a “market perform” rating and set a $6.00 target price on shares of LAVA Therapeutics in a report on Wednesday, December 11th. Leerink Partners reissued a “market perform” rating and set a $2.00 price target (down from $11.00) on shares of LAVA Therapeutics in a research report on Thursday. Finally, Citizens Jmp cut shares of LAVA Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Wednesday, December 11th. Four research analysts have rated the stock with a hold rating and one has assigned a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $4.67.

LAVA Therapeutics Stock Down 7.5 %

NASDAQ LVTX opened at $1.11 on Monday. The firm has a market capitalization of $28.14 million, a PE ratio of -1.08 and a beta of 0.43. The stock’s 50 day moving average is $1.69 and its 200 day moving average is $1.82. LAVA Therapeutics has a twelve month low of $1.08 and a twelve month high of $6.47.

Hedge Funds Weigh In On LAVA Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the stock. Pathway Financial Advisors LLC boosted its stake in LAVA Therapeutics by 70.8% in the 3rd quarter. Pathway Financial Advisors LLC now owns 102,500 shares of the company’s stock worth $170,000 after purchasing an additional 42,500 shares in the last quarter. XTX Topco Ltd purchased a new position in LAVA Therapeutics in the second quarter worth about $55,000. Finally, Virtu Financial LLC bought a new position in shares of LAVA Therapeutics in the third quarter worth approximately $32,000.

About LAVA Therapeutics

LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients.